News and Trends 29 Aug 2018
Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B
The German biotech will partner with Genentech, part of the Roche Group, to develop targeted cancer therapies that engage both innate and adaptive immune cells. Affimed will receive €82M ($96M) upfront from the US giant to develop its immunotherapy ROCK (Redirected Optimized Cell Killing) platform, which uses both natural killer cells and T-cells to target […]
